

In re Application of: ~~TRADEMARK~~ Cesario Aguilar Rubido,
et al.
Serial No.: 09/857,402

Attorney Docket No. 976-11 PCT/US

Confirmation No.: Unassigned

Filed: June 1, 2001

For: PREPARATIONS CONTAINING VIRUS-LIKE
PARTICLES AS IMMUNOPOTENTIATORS
ADMINISTERED THROUGH THE MUCOSA

ASSISTANT COMMISSIONER FOR PATENTS
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment in the above-identified application.

Small entity status of this application under 37 C.F.R. 1.9 and 1.27 has been established by a verified statement previously submitted.

A verified statement to establish small entity status under 37 C.F.R. 1.9 and 1.27 is enclosed.

No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA
TOTAL	* 13	MINUS	** 20	= 0	
INDEP.	* 1	MINUS	*** 3	= 0	

SMALL ENTITY		OR	OTHER THAN A SMALL ENTITY	
RATE	ADDL. FEE		RATE	ADDL. FEE
x 9=	\$		x 18=	\$
x 40=	\$		x 80=	\$
x 135=	\$		x 270=	\$
TOTAL	\$ 0.00		TOTAL	\$ 0.00

FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIMS

* If the entry in Column 1 is less than the entry in Column 2, write "0" in Column 3.


** If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" in this space is less than 20, write "20" in this space.

*** If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" in this space is less than 3, write "3" in this space. The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest number found from the equivalent box in Column 1 of a prior amendment or the number of claims originally filed.

Please charge my Deposit Account No. 08-2461 in the amount of \$_____. A duplicate copy of this sheet is attached.

A check in the amount of \$____ is attached.

The Commissioner is hereby authorized to charge any fees or additional fees associated with this communication or credit any overpayment to Deposit Account No. 08-2461. A duplicate copy of this sheet is attached.



Prelim
SAW
PATENT

TECH CENTER 1600/2900

OCT 30 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) Julio Cesar Aguilar Rubido, et al. Examiner: Unassigned
Serial No.: 09/857,402 Group Art Unit: Unassigned
Confirmation No.: Docket: 976-11 PCT/US
Filed: June 1, 2001 Dated: August 31, 2001
For: PREPARATIONS
CONTAINING VIRUS-
LIKE PARTICLES AS
IMMUNOPOTENTIATORS
ADMINISTERED
THROUGH THE MUCOSA

Assistant Commissioner for Patents
Washington, DC 20231

*I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to:
Assistant Commissioner for Patents, Washington, D.C.*

*20231 on August 31, 2001
Dated: 8/31/01 J. Borgne*

PRELIMINARY AMENDMENT

Sir:

Prior to examination on the merits, please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 1-10 and add the following new claims.

11. (New) A vaccine formulation suitable for nasal administration, comprising:

- a surface antigen from a virus, and
- a non-living vaccine antigen synergizing in adjuvant effect with said surface antigen, wherein the surface antigen and vaccine antigen are each present up to about 1 mg.

Sub 3/27